In part 1 of 5, panel moderator gives an overview of the Special Report focusing on the approval of Xanomeline and tropism chloride capsules for schizophrenia.
Embracing New Therapies in Schizophrenia Management
In part 2 of 5, experts discuss the unique mechanism of xanomeline and trospium choloride capsules for the treatment of schizozphrenia.
In part 3 of 5, experts discuss the pivotal trials evaulating xanomeline and trospium chloride capsules (Cobenfy) for schizophrenia.
In part 4 of 5, experts discuss medication adherence to schizophrenia treatments, particularly of xanomeline and trospium choloride capsules for schizophrenia.
In part 5 of 5, experts discuss ongoing unmet needs and future research priorities in schizophrenia management.
Advertisement
Advertisement
Trending on HCPLive
1
Why Aldosterone Has Become a Key Target in CKD Care, With Marc Richards, MD
2
Survey Shows Peptide Misinformation, Misuse Rising in US
3
Expanding Era of Evidence-Based CKD Care, With Marc Richards, MD
4
Hidden Operating Room Allergens: Dyes, Implants, Chlorhexidine Overwash
5